Page 3 - Samir Parekh News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Samir parekh. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Samir Parekh Today - Breaking & Trending Today

From War-Torn Beirut to Myeloma Research in NY

Tarek Mouhieddine, MD, grew up in war-torn Lebanon and is now building a career studying multiple myeloma as a hem-onc in New York. ....

United States , New York , Tarek Mouhieddine , Samir Parekh , American University Of Beirut , Dana Farber Cancer Institute , National Cancer Institute , Mouhieddine At Icahn School Of Medicine , Icahn School Of Medicine At Mount Sinai , Icahn School , Mount Sinai , American University , Multiple Myeloma , Plasma Cell Myeloma , Alignant Neoplasia , Clinical Research , Clinical Trials , Linical Studies , Biologic Therapy , Bone Marrow , Healthcare And Medical Technology , Ealth And Medical Tech , Ealth And Med Tech , Ealth And Medical Technology , Academic Medicine ,

Master regulator of cell cycle and its role in cancer

Master regulator of cell cycle and its role in cancer
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

E Premkumar Reddy , Hannay Irie , Samir Parekh , Poulikosi Poulikakos , Staceyj Baker , Icahn School Of Medicine At Mount Sinai , Icahn School , Mount Sinai ,

Salvage therapies may benefit patients with multiple myeloma who relapse after CAR-T

Salvage therapies appeared to maintain clinical activity among patients with relapsed/refractory multiple myeloma who relapsed after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy, according to study results.The findings, published in Blood, serve as a benchmark for future clinical trials that aim to improve outcomes among patients who experience disease progression ....

Samir Parekh , Icahn School Of Medicine At Mount Sinai , Memorial Sloan Kettering Cancer Center , Mount Sinai , Cancer Clinical Investigation , Tisch Cancer Institute , Icahn School ,

Alternative immunotherapies improve RRMM survival

Alternative CAR-T and cell therapies increased relapsed multiple myeloma patient survival by 18 months after CAR-T, a study found. ....

Samir Parekh , Tisch Cancer Institute , Translational Research In Multiple Myeloma , Icahn School Of Medicine , Memorial Sloan Kettering Cancer Center , Mount Sinai , B Cell Maturation Antigen , Sham Mailankody , Associate Attending Physician , Translational Research , Multiple Myeloma , Cancer Clinical Investigation , Icahn School ,

Study finds treatment options for patients whose blood cancer relapses after CAR-T

Researchers from Memorial Sloan Kettering Cancer Center (MSK) and Mount Sinai have uncovered treatments that can assist patients with multiple myeloma, a blood cancer, who have tried the immunotherapy CAR-T but have experienced relapses. ....

Samir Parekh , Icahn School Of Medicine At Mount Sinai , Tisch Cancer Institute , Translational Research In Multiple Myeloma , Memorial Sloan Kettering Cancer Center , Mount Sinai , Translational Research , Multiple Myeloma , Cancer Clinical Investigation , Icahn School , Sham Mailankody , Associate Attending Physician , Ar T , Ews India ,